Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.
about
The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkersPerfusion MRI: the five most frequently asked clinical questions.Principles of T2 *-weighted dynamic susceptibility contrast MRI technique in brain tumor imaging.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and scienceReport of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).Comparison of perfusion- and diffusion-weighted imaging parameters in brain tumor studies processed using different software platformsThe evolving role for re-irradiation in the management of recurrent grade 4 glioma.Arterial spin labeling: Pathologically proven superiority over conventional MRI for detection of high-grade glioma progression after treatmentA semi-automated volumetric software for segmentation and perfusion parameter quantification of brain tumors using 320-row multidetector computed tomography: a validation study.The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.How treatment monitoring is influencing treatment decisions in glioblastomas.Conventional and advanced magnetic resonance imaging in patients with high grade glioma.Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.
P2860
Q28608269-086551D4-0615-45D8-AC8B-FA1E7B11EC6CQ30416198-E3A66397-D877-4D1F-BD9D-820B33724DE2Q30818733-BC69B959-FF07-4660-82FA-2A473D45E48AQ30907831-FEECEDB5-1439-4666-BD01-B70193CD8E59Q30938805-E6041356-98D7-4F93-A72C-F4B1FF3ED4D1Q33746514-D494CDDB-783A-42C9-A4B0-6379A7311708Q34331320-0D40D4B0-7142-4FDF-AC65-D3EFA050343DQ36165361-6266251E-B9DE-4987-8CB2-8B43FA168988Q39225727-58DCE556-00DE-46BF-BF33-2CA3D7A6E01FQ41654869-5834C659-E0F9-4B9E-BD86-9A1AC7B22678Q47915193-CF16BAB2-6551-4729-9089-1166A051F99FQ48098509-ADC29357-102B-4E07-99CD-A65DD436A0B9Q48292017-A92ECA5C-D303-40F0-9382-3DE01398ECEAQ52562075-81B5748B-7B61-4798-8B69-4F98DF130D7CQ55459134-CA8CCC88-2E97-498C-9BBA-BE18990B9BF9
P2860
Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@en
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@nl
type
label
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@en
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@nl
prefLabel
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@en
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@nl
P2093
P2860
P356
P1476
Does MR perfusion imaging impa ...... n tumors? A prospective study.
@en
P2093
A J Johnson
G J Lesser
J H Burdette
K P McMullen
M E Zapadka
P2860
P304
P356
10.3174/AJNR.A2811
P577
2011-11-24T00:00:00Z